Association between neuraxial anaesthesia or general anaesthesia for lower limb revascularisation surgery in adults and clinical outcomes: population based comparative effectiveness study

Abstract

Objective

To examine the associations between neuraxial anaesthesia or general anaesthesia and clinical outcomes, length of hospital stay, and readmission in adults undergoing lower limb revascularisation surgery.

Design

Comparative effectiveness study using linked, validated, population based databases.

Setting

Ontario, Canada, 1 April 2002 to 31 March 2015.

Participants

20 988 patients Ontario residents aged 18 years or older who underwent their first lower limb revascularisation surgery in hospitals performing 50 or more of these surgeries annually.

Main outcome measures

Primary outcome was 30 day all cause mortality. Secondary outcomes were in-hospital cardiopulmonary and renal complications, length of hospital stay, and 30 day readmissions. Multivariable, mixed effects regression models, adjusting for patient, procedural, and hospital characteristics, were used to estimate associations between anaesthetic technique and outcomes. Robustness of analyses were evaluated by conducting instrumental variable, propensity score matched, and survival sensitivity analyses.

Results

Of 20 988 patients who underwent lower limb revascularisation surgery, 6453 (30.7%) received neuraxial anaesthesia and 14 535 (69.3%) received general anaesthesia. The percentage of neuraxial anaesthesia use ranged from 0.6% to 90.6% across included hospitals. Furthermore, use of neuraxial anaesthesia declined by 17% over the study period. Death within 30 days occurred in 204 (3.2%) patients who received neuraxial anaesthesia and 646 (4.4%) patients who received general anaesthesia. After multivariable, multilevel adjustment, use of neuraxial anaesthesia compared with use of general anaesthesia was associated with decreased 30 day mortality (absolute risk reduction 0.72%, 95% confidence interval 0.65% to 0.79%; odds ratio 0.68, 95% confidence interval 0.57 to 0.83; number needed to treat to prevent one death=139). A similar direction and magnitude of association was found in instrumental variable, propensity score matched, and survival analyses. Use of neuraxial anaesthesia compared with use of general anaesthesia was also associated with decreased in-hospital cardiopulmonary and renal complications (odds ratio 0.73, 0.63 to 0.85) and a reduced length of hospital stay (−0.5 days, −0.3 to−0.6 days).

Conclusions

Use of neuraxial anaesthesia compared with general anaesthesia for lower limb revascularisation surgery was associated with decreased 30 day mortality and hospital length of stay. These findings might have been related to reduced cardiopulmonary and renal complications after neuraxial anaesthesia and support the increased use of neuraxial anaesthesia in patients undergoing these surgeries until the results of a large, confirmatory randomised trial become available.

Introduction

Although endovascular treatments are increasingly being used for peripheral artery disease, they are less durable, are not suitable for many patients’ arterial disease, and there is equipoise about whether to offer endovascular or surgical revascularisation to candidates suitable for both.^{1 2 3 4} Therefore, lower limb revascularisation surgeries (endarterectomy, patch angioplasty, thromboembolectomy, and arterial bypass) remain commonly performed, despite being costly and high risk procedures.^{5 6 7 8 9} In the United States, 15 000-20 000 lower limb bypass surgeries are performed annually.^{5 6} People who undergo these procedures are typically older and have multiple comorbidities.^{10 11} These patients have a high risk of postoperative morbidity and mortality and often require long hospital stays.^{1 9 12} The cost of each lower limb revascularisation procedure can exceed $120 000 (£91 552; €101 406.^{5 6} Interventions to improve clinical outcomes and decrease resource use are required for patients undergoing these surgeries.

Neuraxial (epidural or spinal) anaesthesia is commonly used worldwide and could represent one approach to improving outcomes in patients after lower limb revascularisation. Neuraxial anaesthesia has been shown to improve coagulation, increase peripheral blood flow, avoid airway instrumentation and mechanical ventilation, and blunt surgical stress responses.^{13 14 15 16 17} Systematic reviews of randomised controlled trials have found that, compared with general anaesthesia, neuraxial anaesthesia might reduce the risk of pneumonia, venous thromboembolism, and mortality after heterogeneous types of surgery.^{18 19} However, a systematic review limited to four small randomised controlled trials enrolling patients who underwent lower limb revascularisation surgery reported that only the risk of pneumonia was lower after neuraxial anaesthesia.²⁰ Observational studies comparing neuraxial anaesthesia with general anaesthesia for lower limb revascularisation surgery report inconsistent findings and are limited owing to confounding by indication.^{21 22 23} This confounding occurs because anaesthetic techniques might be chosen based on patient, provider, and hospital characteristics, and these characteristics might be associated with outcomes.²⁴

To better understand the relations between type of anaesthesia for lower limb revascularisation surgery and clinical outcomes, we conducted a population based comparative effectiveness study using recommended methods to account for confounding by indication.²⁴ We hypothesised that use of neuraxial anaesthesia instead of general anaesthesia for adults undergoing lower limb revascularisation surgery would be associated with improved clinical outcomes.

Methods

Design, setting, and protocol

We conducted a population based comparative effectiveness study in Ontario, Canada. Except when indicated, all study methods were preplanned and prespecified in a protocol registered at the Center for Open Science (https://osf.io/sy4xu/) before the study was initiated. Because our study relied on routinely collected, anonymised data, it was exempt from research ethics review. Reporting followed recommended guidelines.^{25 26}

Data sources

Ontario residents with a valid healthcare card receive universal access to publicly funded healthcare in Ontario. Ontario healthcare data are recorded in administrative datasets by ICES, an independent health research institute.^{27 28} In this study we used several ICES datasets: the Discharge Abstract Database, which captures hospital admissions and discharges, diagnoses, and procedures; the Ontario Health Insurance Plan Database, which captures physician claims; the National Ambulatory Care Reporting System, which captures emergency and outpatient care; the Continuing Care Reporting System, which captures long term and respite care; the Ontario Drug Benefits Database, which captures prescription drug claims for residents aged 65 years and older; and the Registered Persons Database, which captures deaths.

Participants

We identified Ontario residents aged 18 years and older who underwent lower limb revascularisation surgery, including an infrainguinal arterial bypass or repair (ie, endarterectomy, patch angioplasty, or thromboembolectomy) between 1 April 2002 and 31 March 2015 using Canadian Classification of Intervention (CCI) codes (starting with 1KG76 and 1KG80, except 1KG80GQRN (endovascular stent repair)). These codes have been validated and used in previous studies conducted at ICES.^{29 30 31} To ensure patient level data, we only included data on the first surgery for patients who underwent multiple lower limb revascularisation surgeries during the study period. We excluded patients who underwent a lower limb revascularisation surgery that required suprainguinal inflow (eg, aortobifemoral or axillobifemoral bypass). We also excluded those receiving surgery at hospitals performing fewer than 50 lower limb revascularisation surgeries annually, as vascular surgery is provided in regional centres in Ontario and therefore procedures at low volume hospitals represent atypical care.

Exposure variables

The type of anaesthesia was captured from the Discharge Abstract Database; reabstraction (ie, duplicate data extraction from the same chart by independent reviewers) shows 94% agreement.³² Contraindications to use of neuraxial anaesthesia include patient refusal, infection at the intended injection site, use of anticoagulants or certain antiplatelet agents, severe uncorrected hypotension, increased intracranial pressure, an anticipated long duration of surgery, and an inability to lie still (eg, secondary to cognitive impairment or agitation).³³ Patients who received an epidural or spinal anaesthetic without general anaesthesia were coded as having received neuraxial anaesthesia; patients who received general anaesthesia or neuraxial anaesthesia plus general anaesthesia were coded as having received general anaesthesia. As a sensitivity analysis, we also coded the types of anaesthesia as neuraxial, general, or neuraxial plus general. We did not stratify by type of neuraxial anaesthesia as epidural anaesthesia accounted for only 3.8% of all neuraxial anaesthetics.

Outcome variables

The primary outcome was 30 day all cause mortality (captured from the Discharge Abstract Database and Registered Persons Database). Secondary outcomes were in-hospital cardiopulmonary and renal complications (including major adverse cardiac event (acute coronary syndrome, heart failure, ventricular arrhythmia, or cardiac arrest), pneumonia, venous thromboembolism, or acute kidney injury), captured from type 2 (arising in hospital) diagnostic codes (see supplementary eTable 1), postoperative length of hospital stay (measured from the Discharge Abstract Database as number of days from surgery to hospital discharge), and 30 day readmissions (identified as a new admission in the Discharge Abstract Database within 30 days of the index discharge date from hospital).

Covariates

We captured known, measured covariates that could influence choice of anaesthetic technique and outcomes (ie, produce confounding by indication).^{21 22 23 34 35} Patient characteristics were identified from the Discharge Abstract Database and Canadian Census. Validated case ascertainment algorithms and ICD codes (international classification of diseases, 10th revision) from Discharge Abstract Database records were used to identify high priority diagnoses (coronary artery disease, diabetes, chronic obstructive pulmonary disease, heart failure, and hypertension) and Elixhauser comorbidities in the three years before surgery, respectively.^{36 37 38 39 40} As smoking status is not available in administrative data, we captured physician billing codes for smoking cessation consultations. Preoperative residence in a long term care facility was identified from the Continuing Care Reporting System. Hospital admissions and emergency department visits in the year before surgery were identified from the Discharge Abstract Database and National Ambulatory Care Reporting System, respectively. We calculated Hospital-patient One-year Mortality Risk (HOMR) scores (range from −12 to 76, with higher scores denoting greater risk of death)⁴¹ and the hospital volume of lower limb revascularisation surgery before each index surgery. The Johns Hopkins Adjusted Clinical Group system was used to identify healthcare resource utilisation bands and frailty.^{42 43 44 45} The surgical procedure (using the full 10 digit CCI code), a unique identifier for each hospital, and year of surgery were recorded from the Discharge Abstract Database. Urgency for surgery was categorised as elective (elective admission for surgery), urgent (non-elective admission and surgery ≥72 hours after admission), emergent (non-elective admission and surgery 24-72 hours after admission), and critical (surgery <24 hours after admission) instead of just elective or emergent, to more accurately reflect variations in urgency faced by vascular surgery patients. For people aged 65 years and older, a count of all unique outpatient drugs and a set of specific outpatient drugs (opioids, anticoagulants, antiplatelets, antipsychotics, benzodiazepines, β blockers, dementia drugs, insulin, steroids, and oral diabetes drugs) received in the six months before surgery were identified.⁴⁶ We also collected data on the annual prevalence of antiplatelet and anticoagulant use by these patients.

Statistical analyses

Based on reported differences in mortality between patients who received neuraxial versus general anaesthesia after lower limb revascularisation surgery (2.2% v 1.1%),²³ we estimated that we would require 2817 participants or more in each study arm to detect a difference in 30 day mortality at a 5% significance level with 90% power. A conservative estimate of 10 events for each covariate for our prespecified regression model required about 650 deaths.⁴⁷

An investigator who was aware of treatment group status performed all the statistical analyses. We compared covariate balance using standardised differences, with values greater than 0.1 indicating substantive differences.⁴⁸ Outcomes were analysed on an unadjusted and adjusted basis. Assumptions for regression models were tested and met. SAS (SAS Institute) version 9.4 was used for all analyses.

Preplanned analyses

Our primary approach to adjustment used mixed effects regression models that included a random intercept for each hospital. Binary outcomes were modelled using logit-links and binary distributions. We analysed in-hospital cardiopulmonary and renal complications as a composite outcome to improve power. As length of hospital stay typically has a right skewed distribution, this outcome was modelled using a log-link and gamma distribution.⁴⁹ Absolute differences in adjusted outcomes were calculated using predicted estimates, generated across 1000 bootstrap samples using 1:1 resampling with replacement.⁵⁰ The centile method was used to define effect sizes and 95% confidence intervals.

Adjusted models included anaesthetic type, age, sex, rural versus urban residence, neighbourhood income fifth, surgical urgency, the specific surgical procedure, a multiplicative interaction between the surgical procedure and urgency, comorbidities (coronary artery disease, chronic obstructive pulmonary disease, diabetes, heart failure, hypertension, and each Elixahauser comorbidity not captured by these validated case ascertainment algorithms),^{36 37 38 39 40} preadmission residence in a long term care facility, frailty,^{42 43 44} hospital admission and emergency department visits in the year before surgery, resource utilisation band (Adjusted Clinical Group),⁵¹ hospital lower limb revascularisation volume, HOMR score, smoking cessation consultations, and year of surgery. Supplementary eTable 2 provides the form of all covariates.

We evaluated the robustness of our primary outcome analysis by performing prespecified sensitivity analyses. A Durbin-Wu-Hausman test of endogeneity was used to evaluate if our primary adjusted analysis was subject to unmeasured confounding.^{52 53 54} To account for unmeasured confounding, we conducted a two stage residual inclusion instrumental variable analysis, which is appropriate for binary and non-normally distributed continuous outcomes.^{52 53 55} Instrumental variable analyses leverage a source of naturally occurring variation to block unmeasured confounders through pseudo-randomisation.^{52 53 55} A commonly used instrumental variable is the hospital preference instrument; this approach assumes that local practice patterns (ie, proportion of neuraxial anaesthesia use for all lower limb revascularisation surgeries at each hospital in the year before each patients’ surgery) influences receipt of the intervention (ie, neuraxial anaesthesia)^{55 56} without influencing outcome except through the intervention. This analysis makes three key assumptions (the first two of which are verifiable): patients who receive care at a hospital that provides a high proportion of neuraxial anaesthesia are more likely to receive such anaesthesia (ie, the instrumental variable is highly correlated with use of neuraxial anaesthesia); attending a hospital with higher use of neuraxial anaesthesia does not influence outcome, except through use of neuraxial anaesthesia (ie, the instrumental variable is not correlated with 30 day mortality except through use of neuraxial anaesthesia), and attending a hospital with high use of neuraxial anaesthesia is not influenced by patients’ unmeasured characteristics.^{55 57} Next, we performed a propensity score matched analysis, when we matched exactly on hospital and then within 0.2 standard deviations of the logit of the propensity score using a greedy matching algorithm.⁵⁸ The propensity score was derived from a logistic regression model using anaesthetic type as the dependent variable and all measured covariate data as predictors. We then ran our primary analysis using a Cox proportional hazards model with a random effect for each hospital. The analysis was rerun limited to patients aged 65 years and older so we could adjust for outpatient prescription drug use (anticoagulants, antiplatelet agents, opioids, antipsychotics, benzodiazepines, insulin, oral diabetic agents, oral corticosteroids, and total number of prescription drugs). Finally, we conducted a formal quantitative bias analysis, using the E-value method as previously described, to estimate the effect size of a missing confounder that would be required to move our primary effect estimate to the null value.⁵⁹

We evaluated for possible effect measure modification by introducing multiplicative interaction terms between anaesthetic type and covariates into our primary regression model. These covariates included chronic obstructive pulmonary disease, surgical urgency, frailty, previous diagnosis of peripheral artery disease, and the specific surgical procedure.

Data were missing for 0.09% of participants for the covariate rural versus urban residence and 0.29% of participants for the covariate neighbourhood income fifth. We imputed these covariates with the central measure of tendency (for neighbourhood income fifth) or most common value (for rural versus urban residence).

Post hoc analyses

We conducted several post hoc analyses requested by peer reviewers. Firstly, we re-estimated our primary outcome association after also including those who received surgery in hospitals performing fewer than 50 lower limb revascularisation surgeries annually. Secondly, we re-ran our sensitivity analysis limited to patients aged 65 years and older to additionally adjust for outpatient β blocker and dementia drug use. Thirdly, we included cerebrovascular events (transient ischaemic attack or ischaemic or haemorrhagic stroke, captured from type 2 diagnostic codes) (see supplementary eTable 2) as a secondary outcome and estimated fully adjusted associations between anaesthetic type and each of the components of our composite cardiopulmonary and renal complications outcome.

Patient and public involvement

This was a secondary analysis of healthcare data making it difficult to involve patients or members of the public in this research as it required specialist research training. No patients were involved in setting the research question or the outcome measures, nor were they involved in developing plans for recruitment, design, or implementation of the study. No patients were asked to advise on interpretation or writing up of the results.

Results

Among 26 871 lower limb revascularisation surgeries performed in the Ontario hospitals in this study, 20 988 patients were included (fig 1). Of these patients, 6453 (30.7%) received neuraxial anaesthesia and 14 535 (69.3%) general anaesthesia. The percentage of neuraxial anaesthesia use ranged from 0.6% to 90.6% across the hospitals. Use of neuraxial anaesthesia declined by 17% over the study period (fig 2).

Fig 1.

Flow of patients through the study

Fig 2.

Loess smoothed plot of percentage of neuraxial anaesthesia use across the study period. Shaded areas around the plotted line represent 95% confidence intervals

Table 1 shows the characteristics of the study patients. The participants had multiple associated comorbidities and most received an infrainguinal arterial bypass (78.6%) either electively (60.1%) or urgently (27.5%). Patients who received neuraxial anaesthesia were older; more often had chronic obstructive pulmonary disease, diabetes, and a previous diagnosis of peripheral artery disease; and more often received an arterial bypass and underwent surgery on an elective basis. Patients who received general anaesthesia more often had cardiac valvular disease, underwent surgery on a critical basis, and received an infrainguinal arterial repair (endarterectomy, patch angioplasty, or thromboembolectomy).

Table 1.

Characteristics of 20 988 participants stratified by anaesthetic technique used for lower limb revascularisation surgery. Values are numbers (percentages) unless stated otherwise

Characteristics	Neuraxial anaesthesia (n=6453)	General anaesthesia (n=14 535)	Absolute standardised difference*
Personal characteristics
Mean (SD) age (years)	70.6 (10.7)	67.6 (12.7)	0.25
Women	2132 (33.0)	4763 (32.8)	0
Rural residence	1071 (16.6)	2639 (16.3)	0
Long term care facility resident	159 (2.5)	233 (1.6)	0.06
Income fifth:
1 (lowest)	1569 (24.3)	3554 (24.5)	0
2	1419 (22.0)	3167 (21.8)	0
3	1231 (19.1)	2758 (19.0)	0
4	1173 (18.2)	2618 (18.0)	0.01
5 (highest)	1061 (16.4)	2438 (16.8)	0.01
Smoking cessation consultation in year before surgery	168 (2.6)	375 (2.6)	0
Mean (SD) HOMR score†	31.7 (6.0)	31.0 (6.5)	0.11
Comorbidities recorded in 3 years before surgery
Alcohol misuse	176 (2.7)	417 (2.9)	0.01
Atrial fibrillation	569 (8.8)	1228 (8.5)	0.01
Blood loss anaemia	755 (11.7)	1647 (11.3)	0.01
Cancer	382 (5.9)	865 (6.0)	0
Cardiac valvular disease	219 (3.4)	908 (6.3)	0.14
Cerebrovascular disease	432 (6.7)	881 (6.1)	0.02
Chronic kidney disease	587 (9.1)	997 (6.9)	0.08
Chronic obstructive pulmonary disease	2639 (40.9)	5260 (36.2)	0.10
Coagulopathy	190 (2.9)	656 (4.5)	0.08
Deficiency anaemia	65 (1.0)	121 (0.8)	0.02
Dementia	126 (2.0)	219 (1.5)	0.04
Depression	182 (2.8)	427 (2.9)	0.01
Diabetes	3162 (49.0)	6301 (43.4)	0.11
Dialysis	322 (5.0)	558 (3.8)	0.06
Drug misuse	30 (0.5)	63 (0.4)	0.01
Frailty	1383 (21.4)	2710 (18.6)	0.07
Heart failure	1588 (24.6)	3047 (21.0)	0.09
Hemiparesis or hemiplegia	59 (0.9)	106 (0.7)	0.02
Hypertension	5199 (81.0)	11 306 (77.8)	0.08
Liver disease	78 (1.2)	164 (1.1)	0.01
Metastatic cancer	45 (0.7)	146 (1.0)	0.03
Myocardial infarction	871 (13.5)	1919 (13.2)	0
Obesity	134 (2.1)	350 (2.4)	0.02
Peptic ulcer disease	134 (2.1)	243 (1.7)	0.03
Previous diagnosis of peripheral artery disease	2579 (40.0)	4786 (32.9)	0.15
Psychosis	23 (0.4)	75 (0.5)	0.01
Pulmonary circulatory disease	96 (1.5)	295 (2.0)	0.04
Rheumatic disease	69 (1.1)	153 (1.1)	0
Venous thromboembolism	78 (1.2)	185 (1.3)	0.01
Weight loss	113 (1.8)	219 (1.5)	0.02
Healthcare resource use
Emergency department visit in past year	4072 (63.1)	9001 (61.9)	0.02
Hospital admission in past year	2594 (40.2)	5919 (40.7)	0.01
Resource utilisation band:
1 – healthy user	‡	‡	N/A
2 – low morbidity	‡	‡	N/A
3 – moderate	827 (12.8)	1658 (11.4)	0.04
4 – high	1509 (23.4)	3453 (23.8)	0.01
5 – very high	4113 (63.7)	9373 (64.5)	0.02
Lower limb revascularisation surgery
Mean (SD) hospital volume of lower limb revascularisation yearly	1450 (784)	1480 (842)	0.04
Urgency:
Elective	4112 (63.7)	8492 (58.4)	0.11
Urgent	1847 (28.6)	3922 (27.0)	0.04
Emergent	109 (1.7)	326 (2.2)	0.04
Critical	385 (6.0)	1795 (12.4)	0.22
Procedure:
Infrainguinal bypass	5583 (86.5)	10 917 (75.1)	0.29
Using autogenous graft material	3393 (52.6)	6368 (43.8)	0.18
Using synthetic graft material	2044 (31.7)	4171 (28.7)	0.07
Using composite graft material	146 (2.3)	378 (2.6)	0.02
Repair of arteries below inguinal ligament	653 (10.1)	3158 (21.7)	0.32
Using autograft material	159 (2.5)	665 (4.6)	0.11
Using synthetic material	288 (4.5)	871 (6.0)	0.07
Without using above materials	206 (3.2)	1622 (11.2)	0.31

HOMR=Hospital-patient One-year Mortality Risk; NA=not applicable.

^*Difference in prevalence of binary covariates, or average of continuous covariates, between treatment groups without influence of sample size; values greater than 0.1 indicate substantive differences.

^†Range from −12 to 76, with higher scores denoting greater risk of death.

^‡Privacy legislation does not allow reporting of cell sizes of 6 or less, or cells that allow calculation of a cell of 6 or less.

For the 13 176 included patients aged 65 years and older with outpatient prescription drug data, use of anticoagulants remained relatively stable over time, whereas yearly antiplatelet use increased by nearly 10% over the study period (see supplementary eFigure 1).

Primary outcome

Death within 30 days occurred in 204 (3.2%) patients who received neuraxial anaesthesia and 646 (4.4%) who received general anaesthesia (unadjusted odds ratio 0.70, 95% confidence interval 0.61 to 0.83; P<0.001). After multivariable, multilevel adjustment, the risk of 30 day mortality remained lower in patients who received neuraxial anaesthesia (0.68, 0.57 to 0.83; P<0.001) (supplementary eTable 3 provides results of the fully adjusted mixed effects model). This difference corresponds to a bootstrap estimated adjusted absolute risk reduction of 0.72% (95% confidence interval 0.65% to 0.79%) or number needed to treat of 139 (95% confidence interval 127 to 154) to prevent one death at 30 days with use of neuraxial anaesthesia instead of general anaesthesia.

Primary outcome sensitivity and subgroup analyses

Sensitivity analyses

In our quantitative bias analysis using the E-value we estimated that our calculated adjusted odds ratio for 30 day mortality could only be attenuated from 0.68 to 1.0 (the null value) by an unmeasured confounder strongly associated (by an odds ratio of 2.3, above and beyond the measured confounders already accounted for in our analyses) with both use of neuraxial anaesthesia and mortality. Furthermore, the Durbin-Wu-Hausman test suggested that unmeasured confounding was present in the primary outcome adjusted analysis (P<0.001). The hospital preference instrumental variable appeared valid (ie, a strong association was found with use of neuraxial anaesthesia (F statistic=3791), but no correlation with 30 day mortality (ρ=0.02).

Table 2 shows the results of sensitivity analyses. The association between use of neuraxial anaesthesia and decreased 30 day mortality was consistent in instrumental variable, propensity score matched, and survival analyses, and after adjusting for different outpatient prescription drug use (see supplementary eTable 4 for characteristics of the propensity score matched cohorts, eTable 5 for characteristics of the patients with outpatient prescription drug data, and eTable 6 for results of the fully adjusted mixed effects model that included these patients). The association was also consistent in a post hoc analysis that included all patients who underwent lower limb revascularisation surgery in Ontario during the study, including those who received surgery in hospitals performing fewer than 50 lower limb revascularisation surgeries annually.

Table 2.

Results of prespecified and post hoc sensitivity analyses examining association between anaesthetic technique and 30 day mortality in patients who underwent lower limb revascularisation surgery

Analysis	Adjusted odds ratio (95% CI)*	Adjusted absolute difference (95% CI) (%)	P value
Prespecified
Multivariable, mixed effects models (primary approach to adjustment)	0.68 (0.57 to 0.83)	0.72 (0.65 to 0.79)	<0.001
Instrumental variable analysis	0.82 (0.73 to 0.93)	0.61 (0.68 to 0.75)	NA†
Propensity score matched analysis	0.72 (0.58 to 0.89)	1.1 (0.40 to 1.8)	<0.001
Survival analysis	0.72 (0.60 to 0.82)	NA‡	<0.001
Multivariable, mixed effects model using only patients with outpatient prescription drug data to adjust for different preoperative drug use§	0.74 (0.51 to 0.90)	0.99 (0.85 to 1.11)	0.003
Post hoc
Multivariable, mixed effects model using only patients with outpatient prescription drug data and also adjusting for preoperative β blocker and dementia drug use¶	0.74 (0.60 to 0.90)	0.93 (0.80 to 1.1)	0.003
Multivariable, mixed effects model also included patients who had lower limb revascularisation surgery in a low volume centre**	0.74 (0.61 to 0.90)	0.38 (0.30 to 0.46)	0.002

NA=not applicable.

^*Survival analysis measure of association is a hazard ratio instead of odds ratio.

^†P values are not generated for effect measures derived from bootstrap analyses.

^‡Absolute differences cannot be calculated with Cox proportional hazards models as they are rank based instead of probability based.

^§Model also adjusted for differences in outpatient opioid, anticoagulant, antiplatelet, antipsychotic, benzodiazepine, insulin, steroid, and oral diabetes drug use.

^¶Model also adjusted for differences in outpatient opioid, anticoagulant, antiplatelet, antipsychotic, benzodiazepine, β blocker, dementia drug, insulin, steroid, and oral diabetes drug use.

^**Defined as a centre performing fewer than 50 lower limb revascularisation surgeries annually.

Subgroup analyses

No significant heterogeneity was observed for associations between use of neuraxial anaesthesia and 30 day mortality within subgroups of patients with a history of chronic obstructive pulmonary disease (P=0.43), frailty (P=0.68), or peripheral artery disease (P=0.39); those with differing surgical urgency (P=0.14); or among patients who underwent different infrainguinal arterial procedures (P=0.45). When we re-ran our primary analysis with a three level categorical variable as our main exposure, isolated neuraxial anaesthesia (odds ratio 0.71, 95% confidence interval 0.58 to 0.88; P=0.001) but not neuraxial anaesthesia plus general anaesthesia (0.84, 0.64 to 1.10; P=0.21) was significantly associated with an adjusted decrease in 30 day mortality compared with general anaesthesia alone.

Secondary outcomes

Table 3 shows the results of secondary outcome analyses (see supplementary eTable 7 for the incidence of each secondary outcome and unadjusted absolute differences in these outcomes between groups). Compared with patients who received general anaesthesia, those who received neuraxial anaesthesia had a lower unadjusted odds of a major adverse cardiac event, heart failure, pneumonia, venous thromboembolism, acute kidney injury, and cerebrovascular event. After multivariable, multilevel adjustment, use of neuraxial anaesthesia instead of general anaesthesia was associated with a decreased odds of in-hospital cardiopulmonary and renal complications (0.73, 0.63 to 0.85; P<0.001) and a reduced length of hospital stay (−0.5 days, −0.3 to−0.6 days; P<0.001). In a post hoc analysis, after multivariable, multilevel adjustment, neuraxial anaesthesia was also associated with a decreased odds of a major adverse cardiac event (0.72, 0.60 to 0.87; P<0.001).

Table 3.

Results of analyses examining associations between anaesthetic technique and secondary outcomes among the 20 988 study patients who underwent lower limb revascularisation surgery

Secondary outcomes	Unadjusted odds ratio (95% CI)	P value	Adjusted odds ratio (95% CI)	P value
In-hospital cardiac, pulmonary, or renal complications*	0.74 (0.66 to 0.83)	<0.001	0.73 (0.63 to 0.85)	<0.001
Major adverse cardiac event†	0.80 (0.69 to 0.92)	<0.001	0.72 (0.60 to 0.87)	<0.001
Heart failure	0.90 (0.71 to 1.13)	0.39	‡	‡
Pneumonia	0.74 (0.57 to 0.96)	0.02	0.81 (0.60 to 1.11)	0.19
Venous thromboembolism	0.42 (0.24 to 0.73)	0.001	‡	‡
Deep vein thrombosis	0.52 (0.29 to 0.95)	0.04	‡	‡
Pulmonary embolism	0.17 (0.04 to 0.70)	0.004	‡	‡
Acute kidney injury	0.48 (0.34 to 0.67)	<0.001	‡	‡
Cerebrovascular event§	0.38 (0.16 to 0.90)	0.03	‡	‡
Hospital readmissions	1.00 (0.91 to 1.10)	0.98	0.59 (0.32 to 1.10)	0.11
Length of hospital stay (days)	Absolute difference −0.2 (−0.1 to −0.2)	<0.001	Absolute difference −0.5 (−0.3 to −0.6)	<0.001

^*It was decided a priori to analyse the adjusted odds of in-hospital cardiopulmonary and renal complications as a composite outcome to improve power.

^†Includes acute coronary syndrome, heart failure, ventricular arrhythmia, or cardiac arrest.

^‡Number of events was too low to allow for fully adjusted regression modelling.

^§Post hoc analysis; includes transient ischaemic attack and ischaemic or haemorrhagic stroke.

Discussion

In this population based comparative effectiveness study of 20 988 adults who underwent lower limb revascularisation surgery, including infrainguinal arterial bypass or repair, use of neuraxial anaesthesia instead of general anaesthesia was associated with decreased 30 day mortality. This finding persisted in adjusted analyses (controlling for potential confounding factors and clustering of patient data within hospitals) and instrumental variable, propensity score matched, survival, and other sensitivity analyses. Our secondary outcome analyses suggested that decreased mortality after neuraxial anaesthesia might have been related to reduced cardiopulmonary and renal complications among patients who received neuraxial anaesthesia. Neuraxial anaesthesia was also associated with a decreased adjusted length of hospital stay. Despite this, we observed wide variation in use of this type of anaesthesia across hospitals in Ontario, Canada, and an overall noticeable decline in use over the study period.

Our findings are biologically plausible and consistent with results of randomised controlled trials conducted among other populations. Adults undergoing lower limb revascularisation surgery are at high risk of postoperative complications, typically because they are older, are current or former cigarette smokers, and have multiple comorbidities, including diabetes and coronary artery, pulmonary, and chronic kidney disease.^{9 60 61} As neuraxial anaesthesia has been associated with a reduced stress response to vascular surgery and improved postoperative coagulation compared with general anaesthesia, it theoretically might be safer than general anaesthesia for these patients.^{13 14 15 16 17} In potential support of this, we observed statistically significant reductions in cardiac, renal, and thromboembolic complications in adults receiving neuraxial anaesthesia compared with general anaesthesia for lower limb revascularisation surgery, a finding consistent with systematic reviews of randomised controlled trials of patients having various types of surgery.^{18 19} Furthermore, when these patients received neuraxial anaesthesia and general anaesthesia together, the mortality benefit of neuraxial anaesthesia was no longer present, suggesting that provision of mechanical ventilation, general anaesthesia, or both may negate some of the benefits of neuraxial anaesthesia.

Strengths and weaknesses of this study

Our findings should be considered in the context of the study’s strengths and limitations. We used health administrative data that lack information on patient level physiological measures such as blood pressure that might mediate the relation between anaesthetic type and outcome. Additionally, our data were not collected for research purposes and are therefore at risk of misclassification bias. However, our exposure (anaesthetic type) has been validated,³² and mortality was ascertained from the reference standard for mortality data in Ontario. Finally, our data on cardiopulmonary and renal complications were not prospectively collected, and typically complications captured from administrative data have high specificity but variable sensitivity.⁶² Therefore our methods might underestimate the risks of complications, although this would not be expected to differ between treatment groups.

Although we adjusted for the specific type of surgery using the entire 10 digit CCI code describing details of the type of operation performed, we were unable to identify certain potentially important surgical details (eg, arterial bypass inflow and outflow sources or exact anticipated operative durations). This limitation could bias the results of our primary outcome (and some of our sensitivity analyses) away from the null if patients with more complex types of lower limb revascularisation surgeries were more likely to receive general anaesthesia. However, we believe that it would be unlikely for our findings to be entirely explained by differences in surgical complexity between treatment groups or other residual or unmeasured potentially confounding factors, for several reasons. In our quantitative bias analysis we estimated that the calculated adjusted odds ratio for 30 day mortality could only be attenuated to the null by an unmeasured confounder (eg, surgical complexity) strongly associated with both use of neuraxial anaesthesia and mortality.⁵⁹ Furthermore, when we used a prespecified instrumental variable analysis to block the effects of both measured and unmeasured confounders, our effect size remained statistically significant and only slightly attenuated towards the null when compared with methods used to account for measured confounding alone. Therefore, for patients who would be eligible for either neuraxial anaesthesia or general anaesthesia, there might be stronger than associative evidence of benefit for use of neuraxial anaesthesia.

Strengths and weaknesses in comparison to other studies

Our findings seem to be consistent with a recent cohort study of 16 052 patients who underwent lower limb arterial bypass.²³ In that study, use of neuraxial anaesthesia was associated with a shorter adjusted length of hospital stay (−1.66 days, 95% confidence interval −0.02 to−3.29 days) compared with use of general anaesthesia. Also, although underpowered for mortality, the reported absolute risk difference for mortality in that study (1.1%) was similar to the value reported in our study (0.72%). Importantly, our study deals with limitations of previously reported observational studies comparing neuraxial anaesthesia with general anaesthesia after lower limb revascularisation surgery, including that of the recent cohort study.²³ We adjusted for a more complete set of potential confounding factors, conducted sensitivity analyses designed to account for unmeasured confounding, and evaluated a cohort in which the distribution of anaesthetic types was more balanced—that is, only 3.5% of participants in the published cohort study received neuraxial anaesthesia compared with 30.7% of participants in our study.²³

Meaning of the study, unanswered questions, and future research

Our findings have potentially important implications for practice and future research. Despite evidence of benefit with no signal towards harm, use of neuraxial anaesthesia in patients undergoing lower limb revascularisation surgery was recently reported to decrease by 40% between 2011 and 2016 in the US.²³ We also observed a decline in use of neuraxial anaesthesia by 17% for these types of surgeries in Ontario between 2002 and 2015. Utilisation of neuraxial anaesthesia for lower limb revascularisation surgeries was also highly variable between the Ontario hospitals included in our study (ranging from 0.6% to 90.6%).

Variation in use of neuraxial anaesthesia for other types of surgical procedures has also been reported. For example, one study reported wide variation between hospitals in the United Kingdom in use of neuraxial, general, and local anaesthesia for patients undergoing endovascular abdominal aortic aneurysm repair.⁶³ Although the frequency of neuraxial anaesthesia use for total hip and knee arthroplasty has remained relatively unchanged or might have even declined slightly with time in the US, Canada, and the UK,^{64 65 66} its use seems to be increasing for hip fracture surgery in Canada.⁶⁷

We are unable to fully explain the observed decline in use of neuraxial anaesthesia for lower limb revascularisation surgery in our study. Although the increasing use of antiplatelet agents observed during the study period could partly explain the decline, more than 80% of the study patients with outpatient prescription drug data were not taking prescription antiplatelet or anticoagulant drugs preoperatively. Furthermore, no financial incentives are provided for use of neuraxial anaesthesia or general anaesthesia in Ontario. Reported reasons for variation in use of neuraxial anaesthesia for other operations have included patient factors; the specific hospital or treating anaesthetist; whether the treating anaesthetist is board certified; patient’s knowledge, attitudes, perceptions, and concerns about anaesthesia; and surgeon and anaesthetist preferences.^{34 68 69 70 71 72 73} Future research is required to evaluate contributors to declining use of neuraxial anaesthesia for lower limb revascularisation surgery.

With a number needed to treat for mortality estimated at 139, our data suggest that increased use of neuraxial anaesthesia could result in more than 100 lives saved among the 20 000 patients who underwent lower limb revascularisation surgeries performed annually in the US. These estimates must be interpreted with caution given the observational nature of our data, and they highlight the need for a confirmatory randomised controlled trial. However, we believe that confirmatory data from a randomised controlled trial are unlikely to be available soon. Based on our data, powering a randomised controlled trial to show a difference in mortality or end organ complications would require more than 2500 participants in each study arm and would be the largest trial to date of neuraxial anaesthesia in any setting, requiring a large amount of funding and years of multicentre, possibly international recruitment. Use of a validated continuous outcome, such as the Comprehensive Complications Index or World Health Organization Disability Assessment Schedule could substantially reduce the required sample size.^{74 75} Until a confirmatory randomised controlled trial is completed, our findings, combined with the low risk of complications attributable to neuraxial anaesthesia (estimated incidence of permanent injury is 3 to 6 per 100 000 patients treated with this anaesthetic technique⁷⁶), support increased use of neuraxial anaesthesia in patients undergoing lower limb revascularisation surgery without contraindications.

Conclusions

In this population based comparative effectiveness study, we observed wide variation in use of neuraxial anaesthesia for lower limb revascularisation surgery across Ontario hospitals and an overall noticeable decline in its use for this type of surgery over the study period. Despite this, use of neuraxial anaesthesia compared with general anaesthesia for lower limb revascularisation surgery was associated with decreased adjusted mortality and length of hospital stay. These findings might have been related to reduced cardiopulmonary and renal complications after neuraxial anaesthesia. Until results of a large, confirmatory randomised controlled trial become available, this study supports increased use of neuraxial anaesthesia in patients undergoing lower limb revascularisation surgery.

What is already known on this topic

• Leg revascularisation surgeries are frequently performed, yet are costly and high risk procedures

• Commonly used neuraxial (epidural or spinal) anaesthesia improves coagulation, increases peripheral blood flow, avoids airway instrumentation and mechanical ventilation, and blunts surgical stress responses

• Small randomised trials and larger cohort studies limited by confounding by indication have reported inconsistent improvements in clinical outcomes between neuraxial anaesthesia and general anaesthesia

What this study adds

• Use of neuraxial anaesthesia for lower limb revascularisation surgery varied widely across hospitals in Ontario, Canada, and use noticeably declined for this type of surgery over the study period

• After accounting for confounding by indication, use of neuraxial anaesthesia for lower limb revascularisation surgery was associated with decreased 30 day mortality and length of hospital stay compared with use of general anaesthesia

• These findings might have been related to reduced cardiopulmonary and renal complications after neuraxial anaesthesia and support its increased use in patients undergoing lower limb revascularisation surgery until results of a large, randomised trial are available

Web extra.

Extra material supplied by authors

Supplementary information: additional tables e1-e7 and fig e1